AstraZeneca consensus stays positive, analysts see upside for the stock

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 20:26.

AstraZeneca (US6549022043) remains firmly covered in London trading, where the AZN shares are part of the FTSE 100 benchmark. The current analyst consensus on the stock points to a Buy rating with forecast upside, according to recent estimates.

What analysts are signaling now

For AstraZeneca on the London Stock Exchange, 19 of 21 analysts currently recommend buying the shares, while three rate them Hold and one advises selling, based on data compiled by Investing.com.Analyst overview on Investing.com This distribution underpins a broadly positive stance on the large-cap pharma group within the FTSE 100.

The same consensus shows an average 12?month price target of 16,681.3 pence for AstraZeneca, compared with a recent London price around 13,290 pence on June 22, 2026.Price and target data on MarketScreener This implies a potential upside of roughly 22 percent from the latest close, with individual target estimates ranging between about 11,476 and 19,021 pence according to the consensus set.

How the AstraZeneca shares are valued

On June 22, 2026, AstraZeneca shares in London closed at 13,290 pence, up 0.42 percent on the day, with a trading volume of around 1.82 million shares reported on MarketScreener.London quote snapshot for AstraZeneca At this level, Hargreaves Lansdown cites a market capitalization of about £206.1 billion and a price?earnings ratio of 26.48 for the group.Key metrics from Hargreaves Lansdown

Dividend data from the same broker show a yield of 1.78 percent, based on a dividend per share of £1.595 and an ex?dividend date of February 19, 2026, with payment scheduled for March 23, 2026.Dividend details for AstraZeneca These figures frame the current income component for investors alongside the growth expectations reflected in the consensus price targets.

The medicines behind the equity story

AstraZeneca generates most of its revenue with prescription medicines in oncology, cardiovascular, renal and metabolism, respiratory and immunology, and rare disease. Flagship oncology products include Tagrisso for lung cancer and Imfinzi for several tumor types, while Farxiga is a key drug in cardiovascular and renal indications.AstraZeneca annual report product portfolio

Where the AstraZeneca shares trade today

The AstraZeneca shares (US6549022043) most recently traded in London at 13,290 pence on 2026-06-22, 16:35, on the London Stock Exchange.

This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell securities. All data have been carefully researched but cannot be guaranteed. Investors should conduct their own research or consult a qualified advisor before making investment decisions.